2022
Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations
Choudhary GS, Pellagatti A, Agianian B, Smith MA, Bhagat TD, Gordon-Mitchell S, Sahu S, Pandey S, Shah N, Aluri S, Aggarwal R, Aminov S, Schwartz L, Steeples V, Booher RN, Ramachandra M, Samson M, Carbajal M, Pradhan K, Bowman TV, Pillai MM, Will B, Wickrema A, Shastri A, Bradley RK, Martell RE, Steidl UG, Gavathiotis E, Boultwood J, Starczynowski DT, Verma A. Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations. ELife 2022, 11: e78136. PMID: 36040792, PMCID: PMC9427103, DOI: 10.7554/elife.78136.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaMyelodysplastic syndromeNF-kB activationLymphoma SocietyMDS/acute myeloid leukemiaNational InstitutePathogenesis of MDSInterleukin-1 receptor-associated kinase 4Expression of IRAK4Inflammatory-immune pathwaysInflammatory cytokine productionSpecific oncogenic pathwaysCareer development grantsHealth research trainingCritical downstream mediatorCytokine productionMyeloid leukemiaPreclinical modelsNew York State DepartmentXenograft modelImmune pathwaysNF-kB.MDS samplesTRAF6 activationLeukemic growth
2021
Generation of scalable cancer models by combining AAV-intron-trap, CRISPR/Cas9, and inducible Cre-recombinase
Boddu PC, Gupta AK, Kim JS, Neugebauer KM, Waldman T, Pillai MM. Generation of scalable cancer models by combining AAV-intron-trap, CRISPR/Cas9, and inducible Cre-recombinase. Communications Biology 2021, 4: 1184. PMID: 34645977, PMCID: PMC8514589, DOI: 10.1038/s42003-021-02690-1.Peer-Reviewed Original ResearchChallenges in the Evaluation and Management of Toxicities Arising From Immune Checkpoint Inhibitor Therapy for Patients With Myeloid Malignancies
Shallis RM, Bewersdorf JP, Swoboda DM, Wei W, Gowda L, Prebet T, Halene S, Pillai MM, Parker T, Neparidze N, Podoltsev NA, Seropian S, Sallman DA, Gore SD, Zeidan AM. Challenges in the Evaluation and Management of Toxicities Arising From Immune Checkpoint Inhibitor Therapy for Patients With Myeloid Malignancies. Clinical Lymphoma Myeloma & Leukemia 2021, 21: e483-e487. PMID: 33551344, DOI: 10.1016/j.clml.2021.01.003.Peer-Reviewed Original Research
2020
Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience*
Bewersdorf JP, Shallis RM, Gowda L, Wei W, Hager K, Isufi I, Kim TK, Pillai MM, Seropian S, Podoltsev NA, Gore SD, Siddon AJ, Zeidan AM. Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience*. Leukemia & Lymphoma 2020, 61: 2180-2190. PMID: 32362171, PMCID: PMC7603787, DOI: 10.1080/10428194.2020.1759051.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaMedian overall survivalTherapy-related malignanciesOverall survivalMyelodysplastic syndromeMyeloid leukemiaAllogeneic hematopoietic stem cell transplantLonger median overall survivalSingle-center retrospective studyComplex karyotypeHematopoietic stem cell transplantIntensive chemotherapy approachesYale Cancer CenterCharacteristics of patientsSingle-center experienceMinority of patientsStem cell transplantLong-term survivalLow response rateIntensive chemotherapyCenter experienceClinicopathologic characteristicsAdverse prognosisAML patientsCell transplant
2017
Fibroblast Subtypes Regulate Responsiveness of Luminal Breast Cancer to Estrogen
Brechbuhl HM, Finlay-Schultz J, Yamamoto T, Gillen A, Cittelly DM, Tan AC, Sams SB, Pillai M, Elias A, Robinson WA, Sartorius CA, Kabos P. Fibroblast Subtypes Regulate Responsiveness of Luminal Breast Cancer to Estrogen. Clinical Cancer Research 2017, 23: 1710-1721. PMID: 27702820, PMCID: PMC5378660, DOI: 10.1158/1078-0432.ccr-15-2851.Peer-Reviewed Original ResearchConceptsCancer-associated fibroblastsBreast cancer cellsBreast cancerER expressionPatient outcomesCancer cellsEstrogen receptor-positive breast cancerReceptor-positive breast cancerTamoxifen-resistant breast cancer cellsBreast cancer-associated fibroblastsInferior clinical responseMajor clinical complicationsER expression levelsEstrogen-dependent proliferationWorse patient outcomesClin Cancer ResPatient breast tumorsTumor cell sensitivityTumor cell resistanceAntiendocrine therapyTamoxifen therapyClinical responseDisease recurrenceClinical complicationsDevelopment of resistance
2013
Primary Marrow-Derived Stromal Cells: Isolation and Manipulation
Ramakrishnan A, Torok-Storb B, Pillai M. Primary Marrow-Derived Stromal Cells: Isolation and Manipulation. Methods In Molecular Biology 2013, 1035: 75-101. PMID: 23959984, PMCID: PMC3748384, DOI: 10.1007/978-1-62703-508-8_8.Peer-Reviewed Original ResearchConceptsMarrow stromal cellsStem cellsMSC populationsPrimary marrow stromal cellsMultipotent stem cellsImmortalized cell linesStromal cellsPrimary marrowMesenchymal lineagesCellular heterogeneityMesenchymal stem cellsHematopoietic cellsCell linesRare cellsCellsBone marrow mononuclear cellsMarrow mononuclear cellsBone marrow harvestLineagesBone marrowMarrow biopsyMononuclear cellsClinical transplantationMarrow harvestPopulation
2010
MiR-886-3p Down Regulates CXCL12 (SDF1) Expression in Human Marrow Stromal Cells
Pillai M, Yang X, Balakrishnan I, Bemis L, Torok-Storb B. MiR-886-3p Down Regulates CXCL12 (SDF1) Expression in Human Marrow Stromal Cells. PLOS ONE 2010, 5: e14304. PMID: 21179442, PMCID: PMC3001477, DOI: 10.1371/journal.pone.0014304.Peer-Reviewed Original Research
2006
Reduced expression of inducible gelatinase B/matrix metalloproteinase-9 in monocytes from patients with myelodysplastic syndrome: correlation of inducible levels with the percentage of cytogenetically marked cells and with marrow cellularity
Iwata M, Pillai M, Ramakrishnan A, Hackman R, Deeg H, Opdenakker G, Torok-Storb B. Reduced expression of inducible gelatinase B/matrix metalloproteinase-9 in monocytes from patients with myelodysplastic syndrome: correlation of inducible levels with the percentage of cytogenetically marked cells and with marrow cellularity. Blood 2006, 109: 85-92. PMID: 16954500, PMCID: PMC1785081, DOI: 10.1182/blood-2006-05-020289.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBone MarrowCells, CulturedChemokinesCulture Media, ConditionedCytokinesEnzyme InductionFemaleFibroblastsHumansIn Situ Hybridization, FluorescenceLipopolysaccharide ReceptorsMaleMatrix Metalloproteinase 9Middle AgedMonocytesMyelodysplastic SyndromesRecombinant ProteinsReverse Transcriptase Polymerase Chain ReactionRNA, MessengerStromal CellsConceptsMMP-9Myelodysplastic syndromeMarrow cellularityMonocyte populationsMatrix metalloproteinasesGelatinase B/matrix metalloproteinase-9Stromal cellsMCP-1/CCL2IL-8/CXCL8SDF-1/CXCL12Matrix metalloproteinase-9MMP-9 expressionMarker-positive cellsInducible levelsMDS patientsIL-6Healthy donorsMetalloproteinase-9Marrow stromal cellsG-CSFPatientsGM-CSFMonocytesStromal factorsM-CSF